R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Subscribe To Our Newsletter & Stay Updated
